Business Wire

RIX Industries and Element 1 Corporation Partner to Deploy Hydrogen Generators for Fuel Cell Propulsion Systems

8.10.2020 19:39:00 EEST | Business Wire | Press release

Share

RIX Industries (“RIX”), a leading developer of pneumatic energy technology, announced today that it has licensed proprietary methanol-based M-Series hydrogen generator technology from Element 1 Corp (e1). Under the terms of the license agreement, RIX has been granted rights to manufacture and deploy e1’s M-Series on-board hydrogen generators for use in fuel cell mobility applications, including marine vessels and off-road vehicles such as mining trucks, tractors, and heavy-lift trucks in both North America and Europe.

Governments across the globe are striving to reduce harmful emissions into the air and waterways. Tightening regulations combined with corporate sustainability initiatives are driving a massive migration to non-polluting electric propulsion systems, many of which utilize hydrogen fuel cells. RIX’s history of supporting the maritime industry, including the US Navy, together with e1’s methanol to hydrogen generator offers end-users an opportunity to adopt fuel cell motive solutions and work towards a zero-emissions future.

“RIX Industries has a global reputation for excellence and the addition of e1’s class-leading technology to our portfolio strategically aligns with our brand and our growth strategy,” said Bryan Reid, Chief Sales Officer at RIX. “We are focused on the clean energy future and firmly believe that there is a significant market opportunity that can be effectively addressed by RIX incorporating e1’s M-Series hydrogen generator into power solutions.”

Dr. David Edlund, e1 CEO, said, “e1 is delighted and privileged to be collaborating with RIX. They are a first-class manufacturing partner and a long-time authorized supplier to multiple branches of the U.S. military along with a wide range of commercial and industrial end-users. The on-board hydrogen generation technology being licensed to RIX is unique to e1 and is highly enabling to the mass commercialization of fuel cell systems for a wide variety of transportation-related fuel cell applications. I anticipate our relationship with RIX to broaden substantially over the not too distant future,” concluded Dr. Edlund.

The onboard storage of methanol used by e1’s hydrogen generators requires a fraction of the space on a maritime vessel as compared to compressed hydrogen, enabling a significantly greater range between fueling. This range extension is critical for not only marine vessels but also for heavy and medium-duty fuel cell trucks traveling long distances each day.

About RIX Industries:

Founded in 1878, RIX Industries is a technology-focused company, headquartered in Benicia, CA, specializing in the design, development and manufacture of pneumatic energy storage, transfer and control system solutions, including gas generation systems, precision compressor solutions and cryogenic cooling technologies for critical applications in Marine, Aerospace, Land, Energy, Industrial and Medical markets.

Visit www.CreateCompressCool.com for more information.

About Element 1 Corporation:

Element 1 designs and develops novel processes to enable the commercialization of clean-energy products and processes and alternative-energy technology. Through licensing our IP to strategic partners, our mission is to significantly reduce barriers to the adoption of hydrogen technology and fuel cells for a range of applications and to reduce the waste and pollution associated with flaring natural gas.

For more information about Element 1, please visit www.e1na.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Elizabeth Schroeder
Marketing Manager
RIX Industries
Phone: 707.745.7198
E-mail: eschroeder@rixindustries.com

Robert Schluter
President
Element 1 Corporation
Phone: 541.678.5943
E-mail: robert@e1na.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye